CMS Wades Into the Opioid Debate
This article was originally published in RPM Report
Reducing prescription drug abuse is a high priority item for several key legislators and for the Obama Administration. Proposed new rules for Medicare drug plan sponsors might help—but they also underscore the growing tension among the many different stakeholders in the pharmaceutical supply chain.
You may also be interested in...
CMS is backing down from some of the more controversial ideas in what would have been a sweeping update to the rules for Part D, after facing broad opposition. However, the bigger message from the proposed rule is that CMS’ isn’t going to stop trying to improve Part D – and one relatively minor provision that is moving forward may recruit more outsiders to that cause.
The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.
CMS instructions to Part D sponsors cite elimination of waste as a reason to require plans to confirm members want a refill. Draft call letter also addresses expanding drug utilization reviews beyond opioids, added controls on compounded drugs.